MRI in Neuromuscular Diseases: An Emerging Diagnostic Tool and Biomarker for Prognosis and Efficacy
- PMID: 32495452
- DOI: 10.1002/ana.25804
MRI in Neuromuscular Diseases: An Emerging Diagnostic Tool and Biomarker for Prognosis and Efficacy
Abstract
There is an unmet need to identify biomarkers sensitive to change in rare, slowly progressive neuromuscular diseases. Quantitative magnetic resonance imaging (MRI) of muscle may offer this opportunity, as it is noninvasive and can be carried out almost independent of patient cooperation and disease severity. Muscle fat content correlates with muscle function in neuromuscular diseases, and changes in fat content precede changes in function, which suggests that muscle MRI is a strong biomarker candidate to predict prognosis and treatment efficacy. In this paper, we review the evidence suggesting that muscle MRI may be an important biomarker for diagnosis and to monitor change in disease severity. ANN NEUROL 2020;88:669-681.
© 2020 American Neurological Association.
References
-
- Matsumura K, Nakano I, Fukuda N, et al. Proton spin-lattice relaxation time of Duchenne dystrophy skeletal muscle by magnetic resonance imaging. Muscle Nerve 1988;11:97-102.
-
- Kuriyama M, Hayakawa K, Konishi Y, et al. MR imaging of myopathy. Comput Med Imaging Graph Off J Comput Med Imaging Soc 1989;13:329-333.
-
- Ma J. Dixon techniques for water and fat imaging. J. Magn. Reson. Imaging 2008;28:543-558.
-
- Burakiewicz J, Sinclair CDJ, Fischer D, et al. Quantifying fat replacement of muscle by quantitative MRI in muscular dystrophy. J Neurol 2017;264:2053-2067.
-
- Kan HE, Scheenen TWJ, Wohlgemuth M, et al. Quantitative MR imaging of individual muscle involvement in facioscapulohumeral muscular dystrophy. Neuromusc. Disord. 2009;19:357-362.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical